Acumen Pharmaceuticals (ABOS) Net Income (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Net Income of -$21.2 million for Q1 2026, up 14.04% sequentially from -$24.6 million in Q4 2025, and up 26.86% YoY from -$16.7 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Net Income (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Net Income for 7 years, with the latest figure at -$21.2 million in Q1 2026.
- Quarterly Net Income rose 26.86% year-over-year to -$21.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$112.5 million (up 5.24% YoY) and the FY2025 annual result came in at -$201.9 million, down 29.31% from the prior year.
- Net Income improved to -$21.2 million in Q1 2026 per ABOS's latest filing, from -$24.6 million in the prior quarter.
- Over five years, Net Income peaked at -$9.2 million in Q1 2022 and troughed at -$51.2 million in Q3 2022.
- A 5-year average of -$23.3 million and a median of -$21.6 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2023: Net Income tumbled 1205.51% in 2022, then jumped 74.77% in 2023.
- Over 5 years, Net Income stood at -$14.1 million in 2022, then fell by 4.03% to -$14.7 million in 2023, then plunged by 161.32% to -$38.4 million in 2024, then soared by 35.96% to -$24.6 million in 2025, then gained by 14.04% to -$21.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$21.2 million, -$24.6 million, and -$25.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | -32.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.54 Mn |
| Mar 31, 2026 | -21.15 Mn |
| Dec 31, 2025 | -24.61 Mn |
| Sep 30, 2025 | -25.94 Mn |
| Jun 30, 2025 | -40.78 Mn |
| Mar 31, 2025 | -28.92 Mn |
| Dec 31, 2024 | -38.43 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -21.57 Mn |
| Mar 31, 2024 | -14.77 Mn |
| Dec 31, 2023 | -14.70 Mn |
| Sep 30, 2023 | -12.92 Mn |
| Jun 30, 2023 | -11.63 Mn |
| Mar 31, 2023 | -13.18 Mn |
| Dec 31, 2022 | -14.13 Mn |
| Sep 30, 2022 | -51.19 Mn |
| Jun 30, 2022 | -22.91 Mn |
| Mar 31, 2022 | -9.24 Mn |
| Dec 31, 2021 | -8.39 Mn |
| Sep 30, 2021 | -3.92 Mn |